独家 | 绿谷深陷经营困境，停产阿尔茨海默病药物

Core Viewpoint - The company, Green Valley Pharmaceutical Technology, has halted the production of its controversial drug, Glycyrrhizin Sodium Capsules, which is intended for the treatment of mild to moderate Alzheimer's disease, due to severe operational pressures and cash flow issues [2][4][6]. Group 1: Product and Regulatory Status - Glycyrrhizin Sodium Capsules received conditional approval from the National Medical Products Administration in November 2019, with requirements for further studies on carcinogenicity and pharmacological mechanisms [2]. - The drug's international Phase III clinical trial, which aimed to recruit 2,046 participants across China, the U.S., and Europe, was stopped in May 2022 due to factors such as the pandemic and funding issues [2][4]. - The company announced on May 30, 2025, that it would cease operations related to the Glycyrrhizin Sodium product line, pending the approval of its drug registration certificate [2][3]. Group 2: Industry Context and Challenges - Alzheimer's disease presents a significant challenge for the medical community, with global pharmaceutical companies investing hundreds of billions of dollars in research, yet most have failed to produce effective treatments [4]. - The company previously conducted post-marketing clinical research on Glycyrrhizin Sodium, involving 3,300 patients across China, with results expected to be presented at an international academic conference in the second half of 2025 [5]. - The ongoing operational difficulties and cash flow constraints have left the future of this controversial drug uncertain [6].